Abstract

Persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) is a growing clinical problem. To date, no treatment strategy has been established for such infections. Some clinicians continue vancomycin and add either an aminoglycoside or a rifamycin; others switch to linezolid — an oxazolidinone — with or without …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call